1-2 of 2
Keshu Zhou
Close
Sort by
Journal Articles

Safety and efficacy of zanubrutinib in relapsed/refractory marginal zone lymphoma: final analysis of the MAGNOLIA study

Clinical Trials & Observations
Stephen Opat, Alessandra Tedeschi, Bei Hu, Kim M. Linton, Pamela McKay, Sophie Leitch, Morton Coleman, Pier Luigi Zinzani, Jie Jin, Mingyuan Sun, Magdalena Sobieraj-Teague, Peter Browett, Xiaoyan Ke, Catherine Thieblemont, Kirit Ardeshna, Fontanet Bijou, Patricia Walker, Eliza A. Hawkes, Shir-Jing Ho, Keshu Zhou, Zhiyu Liang, Jianfeng Xu, Chris Tankersley, Richard Delarue, Melannie Co, Judith Trotman
Journal: Blood Advances
Blood Adv (2023) 7 (22): 6801–6811.
https://doi.org/10.1182/bloodadvances.2023010668
Published: 2023
Includes: Supplemental data
Journal Articles

Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study

Clinical Trials & Observations
Emmanuel Bachy, Kerry J. Savage, Huiqiang Huang, Yok-Lam Kwong, Giuseppe Gritti, Qingyuan Zhang, Anna Marina Liberati, Junning Cao, Haiyan Yang, Siguo Hao, Jianda Hu, Keshu Zhou, Mario Petrini, Filomena Russo, Huilai Zhang, Wei Sang, Jie Ji, Andrés José María Ferreri, Gandhi Laurent Damaj, Hui Liu, Wei Zhang, Xiaoyan Ke, Chiara Ghiggi, Sha Huang, Xiaotong Li, Hui Yao, Jason Paik, William Novotny, Wenxiao Zhou, Hongjie Zhu, Pier Luigi Zinzani
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4435–4447.
https://doi.org/10.1182/bloodadvances.2022009575
Published: 2023
Includes: Supplemental data